Setmelanotide Research Dosage: Published Protocol Reference
Setmelanotide dosage references vary by route and study context. The database lists Subcutaneous injection: 2-3 mg (adults), Once daily and Subcutaneous injection: 1-2 mg (pediatric, 6-11 years), Once daily. These are research-context references, not a universal protocol.
Direct Answer
Setmelanotide (Imcivree) is FDA-approved for chronic weight management in patients with specific genetic obesity syndromes (POMC, PCSK1, or LEPR deficiency). In its approved population, it produces dramatic and clinically meaningful weight loss. Outside this narrow genetic indication, there is no evidence base. It is not a general obesity treatment - but for research into melanocortin pathway obesity, it is the only approved compound in its class.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Weight Loss & Metabolic
- Best for
- MC4R-pathway genetic obesity (POMC/PCSK1/LEPR deficiency), melanocortin pathway obesity research
Research Dosage References
- <strong>Subcutaneous injection</strong> - 2-3 mg (adults) - Once daily - FDA-approved dose. Start at 2 mg daily, may increase to 3 mg if weight loss is insufficient after 2 weeks. Inject in the abdomen.
- <strong>Subcutaneous injection</strong> - 1-2 mg (pediatric, 6-11 years) - Once daily - Pediatric dosing starts at 1 mg, titrated based on response. Minimum age 6 years.
Half-Life
11 hours.
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Setmelanotide, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Only indicated for obesity due to confirmed POMC, PCSK1, or LEPR deficiency - not for general obesity
- Genetic testing demonstrating variants in POMC, PCSK1, or LEPR required before prescribing
- Risk of depression and suicidal ideation - monitor patients
- Spontaneous erections reported in male patients
- Skin darkening occurs in most patients
- REMS program required due to risk of depression
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Weight Loss in Genetic Obesity (Level A), Hunger Reduction (Level A), and Skin Hyperpigmentation (Level A) |
| Primary citation count | 2 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Setmelanotide Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/setmelanotide-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.